Orphans Dominate Products Seeking End-Of-Year Joy From CHMP
Executive Summary
Five of the nine products that could this week be recommended for EU approval have orphan designation. The final meeting this year of the European Medicines Agency’s key scientific committee, the CHMP, is under way in London.
You may also be interested in...
Clovis Confident, Portola Not: CHMP Decides On EU Marketing Applications
Eight EU marketing authorization applications are up for an opinion this week from the CHMP, the European Medicines Agency committee that recommends whether or not products should be approved.
Products For Flu, Lung Cancer, HIV And TTP Enter Final Stages Of Assessment In EU
Products in the final stages of pre-marketing evaluation at the European Medicines Agency include drugs for influenza, NSCLC, aTTP and HIV infection.
CHMP Negative On PharmaMar's Aplidin In Multiple Myeloma
Clouds are gathering over Spanish firm PharmaMar as the EU's CHMP rejects its multiple myeloma therapy Aplidin. Its reasons are not yet forthcoming.